1. Reconciled Respiratory and Pulmonary Execution & Stop-Cause Profile
| Clinical Trial Metric | Verified Value | Operational Context |
|---|---|---|
| Total Phase II & III Protocols (2018 to 2026) | 1,201 | Deterministic primary MeSH and condition-keyword assignment |
| Active Concurrent Pipeline | 435 | Recruiting, enrolling by invitation, and active follow-up protocols |
| Completed vs Prematurely Stopped | 506 / 146 | 22.39% closed-trial attrition ratio across 652 closed protocols |
| Slow Accrual vs Safety & Futility Stops | 22 / 26 / 12 | Slow accrual (WS1) vs clinical safety (WS4) vs interim futility (WS5) |
| Physical Hospital Site Disclosure Rate | 56.6% | Named hospital campus participations vs anonymized CRO site slots |
2. Leading Consolidated Trial Sponsors Focused on Respiratory and Pulmonary
| Sponsor Hub | Sector | Protocols | Active | Completed | FDA NDA/BLA |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals | Biopharma Industry | 78 | 26 | 48 | 10 |
| Chiesi Farmaceutici S.p.A | Biopharma Industry | 33 | 10 | 13 | 0 |
| Eurofarma Laboratorios | Biopharma Industry | 22 | 2 | 8 | 0 |
| Genrix (Shanghai) Biopharmaceutical Co | Biopharma Industry | 21 | 10 | 6 | 0 |
3. Representative Multi-Center Phase II & III Respiratory and Pulmonary Studies
| NCT Study | Protocol Brief Title | Sponsor | Phase | Status |
|---|---|---|---|---|
| NCT07208591 | To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome | Staidson (Beijing) Biopharmaceuticals Co | Phase III | RECRUITING |
| NCT04965298 | Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole | Norfolk and Norwich University Hospitals NHS Foundation Trust | Phase III | RECRUITING |
| NCT06829784 | TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co | Phase III | RECRUITING |
| NCT06347536 | Supported Rescue Packs Post-discharge in Chronic Obstructive Pulmonary Disease | Guy's and St Thomas' NHS Foundation Trust | Phase III | RECRUITING |
| NCT07121413 | A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis | Shanghai Synvida Biotechnology Co | Phase II | RECRUITING |
| NCT07687459 | Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) | InSilico Medicine Hong Kong Limited | Phase III | RECRUITING |
| NCT07402551 | Phase II Study of RC1416 Injection in COPD | Nanjing RegeneCore Biotech Co | Phase II | RECRUITING |
| NCT07398859 | Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co | Phase II | RECRUITING |
| NCT07464587 | Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | Chia Tai Tianqing Pharmaceutical Group Co | Phase III | RECRUITING |
| NCT07292714 | A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Mabwell (Shanghai) Bioscience Co | Phase II | RECRUITING |
| NCT07516951 | A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis | Chiesi Farmaceutici S.p.A | Phase II | RECRUITING |
| NCT07403487 | Phase II Trial of RC1416 Injection in Asthma | Nanjing RegeneCore Biotech Co | Phase II | RECRUITING |
| NCT05008965 | Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma | Oneness Biotech Co | Phase II | RECRUITING |
| NCT06703073 | JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) | PPD Development, LP | Phase II | RECRUITING |
| NCT06701682 | JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab | PPD Development, LP | Phase II | RECRUITING |
| NCT06701669 | JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart | PPD Development, LP | Phase II | RECRUITING |
Related Therapeutic Condition Hubs & Crosswalks
Compare adjacent clinical cohorts: Oncology and Hematology · Rare Genetic, Women's Health, and Other · Infectious Disease and Vaccines · Neurology, Psychiatry, and Pain, browse the interactive Hospital & Sponsor Directory, or read the Healthcare Price & Patent Cliff Crosswalk.